A research team led by Yoosoo Yang at Sungkyunkwan University, with partners including the Korea Institute of Science and Technology and Incheon National University, reported a nanotechnology-based strategy to selectively manipulate tumor-derived extracellular vesicles (TEVs). The approach is designed to reprogram how tumors communicate with the immune system. The platform uses engineered methods aimed at altering TEV function so that downstream immune responses shift toward attack rather than suppression. The report positions the method as a “switch” that can both interfere with tumor growth and improve immune clearance. For the immunotherapy pipeline, TEV targeting is attractive because it addresses a mechanism often upstream of classic checkpoints—potentially offering combination opportunities if efficacy and safety translate beyond preclinical models.